Merck and Moderna Announce mRNA Vaccine Reduces Melanoma Recurrence Risk by 42 Percent
A Phase 3 trial shows a personalized mRNA vaccine combined with immunotherapy significantly improves outcomes for high-risk melanoma patients after surgery.
What happened
Merck and Moderna released results from the INTerpath-001 Phase 3 clinical trial of Intismeran Autogene, a personalized mRNA vaccine designed from each patient's tumor mutations. The trial enrolled 1,137 people with high-risk melanoma who had undergone complete tumor removal. Participants receiving the vaccine plus Pembrolizumab (an immunotherapy drug) showed a 42 percent reduction in recurrence or death risk compared to those receiving Pembrolizumab alone over an average 24.6-month follow-up period. At trial end, 82.2 percent of the combined-treatment group remained recurrence-free versus 70 percent of the Pembrolizumab-only group. The vaccine also reduced metastasis risk by 38 percent. Mild side effects including fever, fatigue, and injection-site pain were reported, consistent with earlier trials.
Context
Melanoma kills over 50,000 people globally annually despite high survival rates when caught early. The trial demonstrates that tumor-specific mRNA vaccines can improve conventional immunotherapy outcomes in a Phase 3 setting—the final stage before regulatory review. The vaccine's design, which identifies patient-specific tumor mutations to train the immune system, represents a shift toward personalized cancer medicine. Researchers have indicated similar approaches may apply to other cancers; a separate trial showed comparable mRNA vaccines can improve pancreatic cancer survival. However, scaling personalized vaccine production to large populations while maintaining affordability remains a logistical and economic challenge. The therapy is not preventive but therapeutic, designed to reduce recurrence risk after surgery in high-risk patients.